

Glycosylated Hemoglobin and Risk of Colorectal Cancer in Men and Women, the European Prospective Investigation into Cancer and Nutrition

Sabina Rinaldi,¹ Sabine Rohrmann,² Mazda Jenab,¹ Carine Biessy,¹ Sabina Sieri,³ Domenico Palli,⁴ Rosario Tumino,⁵ Amalla Mattiello,⁶ Paolo Vineis,⁷ Alexandra Nieters,² Jakob Linseisen,² Tobias Pischon,⁹ Heiner Boeing,⁹ Göran Hallmans,¹⁰ Richard Palmqvist,¹¹ Jonas Manjer,¹² Elisabet Wirfält,¹³ Francesca L. Crowe,¹⁴ Kay-Tee T. Khaw,¹⁵ Sheila Bingham,¹⁶ Anne Tjønneland,¹⁷ Anja Olsen,¹⁷ Kim Overvad,¹⁸ Eiliv Lund,¹⁹ Guri Skeie,¹⁹ Françoise Clavel-Chapelon,²⁰ Marie-Christine Boutron-Ruault,²⁰ Blandine de Lauzon-Guillain,²⁰ Eva Ardanaz,²¹ Paula Jakszyn,²² Jose Ramon Quiros,²³ Maria-Dolores Chirlaque,²⁴ Maria-Jose Sanchez,²⁵ Miren Dorransoro,²⁶ Antonia Trichopoulou,²⁷ Pagona Lagiou,²⁷ Dimitrios Trichopoulos,²⁷ H. Bas Bueno-de-Mesquita,²⁸ Fränzel J.B. van Duijnhoven,²⁸ Petra H.M. Peeters,²⁹ Nadia Slimani,¹ Pietro Ferrari,¹ Graham B. Byrnes,¹ Elio Riboli,⁸ and Rudolf Kaaks²

¹IARC, Lyon, France; ²German Cancer Research Centre, Division of Cancer Epidemiology, Heidelberg, Germany; ³Epidemiology Unit, National Cancer Institute, Milan, Italy; ⁴Molecular and Nutritional Epidemiology Unit, CSPO-Scientific Institute of Tuscany, Florence, Italy; ⁵Cancer Registry, Azienda Ospedaliera "Civile M.P. Arezzo," Ragusa, Italy; ⁶Dipartimento di Medicina Clinica e Sperimentale, Università Federico II, Naples, Italy; ⁷Environmental Epidemiology, Imperial College and ⁸Division of Epidemiology, Public Health and Primary Care Faculty of Medicine, Imperial College, London, United Kingdom; ⁹Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany; ¹⁰Public Health and Clinical Medicine, Nutrition Research and ¹¹Department of Medical Biosciences, Pathology, Umeå University hospital, Umeå, Sweden; ¹²Department of Surgery, Malmö University Hospital, Malmö, Sweden; ¹³Department of Clinical Sciences in Malmö/Nutrition Epidemiology, Lund University, Lund, Sweden; ¹⁴Cancer Research UK Epidemiology Unit, University of Oxford, Oxford, United Kingdom; ¹⁵Clinical Gerontology Unit, Addenbrooke's Hospital and ¹⁶MRC Dunn Human Nutrition Unit, Cambridge, UK and MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ¹⁷Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; ¹⁸Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ¹⁹Institute of Community Medicine, University of Tromsø, Tromsø, Norway; ²⁰Inserm (Institut National de la Santé et de la Recherche Médicale), ERI 20/Université Paris-Sud, EA 4045, IFR 69/Institut Gustave Roussy, Villejuif, France; ²¹Public Health Institute of Navarra Pamplona, Spain and CIBER Epidemiología y Salud Pública (CIBERESP), Pamplona, Spain; ²²Epidemiology Department, Catalan Institute of Oncology, Barcelona, Spain; ²³Consejería de Salud y Servicios Sanitarios, Asturias, Spain; ²⁴Epidemiology Department, Murcia Health Council, CIBER en Epidemiología y Salud Pública (CIBERESP), Murcia, Spain; ²⁵Andalusian School of Public Health and CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain; ²⁶Public Health Department of Gipuzkoa, Basque Government, Spain; ²⁷University of Athens, School of Medicine, Department of Hygiene and Epidemiology, Athens, Greece; ²⁸The National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; and ²⁹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

Abstract

Although large-scale prospective cohort studies have related hyperglycemia to increased risk of cancer overall, studies specifically on colorectal cancer have been generally small. We investigated the association between prediagnostic levels of glycosylated hemoglobin (HbA1c), a marker for average glucose level in blood, and colorectal cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition cohort. One thousand and

twenty-six incident colorectal cancer cases (561 men and 465 women) and 1,026 matched controls were eligible for the study. Multivariate conditional logistic regression was used to estimate odds ratios (ORs) adjusted for possible confounders. Increasing HbA1c percentages were statistically significantly associated with a mild increase in colorectal cancer risk in the whole population [OR, 1.10; 95% confidence interval (CI), 1.01, 1.19 for a 10% increase in HbA1c]. In women,

Received 5/30/08; revised 8/6/08; accepted 8/18/08.

Grant support: The European Prospective Investigation into Cancer and Nutrition study was funded by European Commission: Public Health and Consumer Protection Directorate 1993-2004; Research Directorate-General 2005; Ligue contre le Cancer (France); Société 3M (France); Mutuelle Générale de l'Éducation Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM); German Cancer Aid; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; the participating regional governments and institutions of Spain; the CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Cancer Research UK; Medical Research Council, UK; the Stroke Association, UK; British Heart Foundation; Department of Health, UK; Food Standards Agency, UK; the Wellcome Trust, UK;

Greek Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer; Italian National Research Council; Dutch Ministry of Public Health, Welfare and Sports; Dutch Ministry of Health; Dutch Prevention Funds; LK Research Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skane, Sweden; and Norwegian Cancer Society. The present study was funded by National Cancer Institute grant 1R01CA102460.

Requests for reprints: Sabina Rinaldi, IARC, 150, cours Albert Thomas, Lyon, 69372 Lyon Cedex 08, France. Phone: 33-4-72-73-83-28; Fax: 33-4-72-73-83-61. E-mail: Rinaldi@iarc.fr

Copyright © 2008 American Association for Cancer Research.
doi:10.1158/1055-9965.EPI-08-0495

increasing HbA1c percentages were associated with a statistically significant increase in colorectal cancer risk (OR, 1.16; 95% CI, 1.01, 1.32 for a 10% increase in HbA1c) and with a borderline statistically significant increase in rectum cancer (OR, 1.22; 95% CI, 0.99, 1.50 for a 10% increase in HbA1c). No significant association

with cancer risk was observed in men. The results of the current study suggest a mild implication of hyperglycemia in colorectal cancer, which seems more important in women than in men, and more for cancer of the rectum than of the colon. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3108–15)

Introduction

Lifestyle factors such as physical inactivity, excess body weight, and obesity have been consistently associated with increased colorectal cancer risk (1-4). These factors, particularly central obesity, have numerous metabolic consequences such as insulin resistance, hyperinsulinemia, hyperglycemia, increased serum triglycerides, and lower high-density lipoprotein cholesterol levels (5), most of which have been proposed to be potentially related to colorectal cancer development. In a number of studies, markers of hyperinsulinemia (such as C-peptide or insulin concentrations) have been associated with increased risk of colorectal cancer (6-10). Although diabetes has been repeatedly associated with an increase in colorectal cancer risk (11-13), less is known about the influence of hyperglycemia on the disease among non-diabetics. Only a few epidemiologic studies have investigated the relationship of blood glucose levels with colorectal adenoma and cancer incidence (6, 14, 15) or colorectal cancer mortality (16, 17), but all of these suggested an implication of elevated blood glucose in the etiology of the disease.

Glycosylated hemoglobin (HbA1c) is a form of hemoglobin in which a molecule of glucose is attached to the β -chain of hemoglobin after its exposure to high plasma levels of glucose. It reflects the average blood glucose levels over the past 6 to 8 weeks (18). HbA1c is currently used for monitoring metabolic control in diabetics, and it has also been proposed as a screening tool for the detection of severe glucose intolerance and diabetes (19, 20). Only few prospective epidemiologic studies have addressed the relationship of HbA1c percentages with adenoma or colorectal cancer risk (21-25) with variable results: two studies, including a case-cohort analysis undertaken within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort, indicated an increase in colorectal cancer risk with increasing HbA1c percentages (23, 25), whereas three others indicated no relationship at all (21, 22, 24). A study based on Swedish populations showed a direct association of HbA1c with colorectal cancer risk only at very high concentrations (top decile levels; ref. 15). Most of these studies had a relatively small sample size (between 67 and 380 case subjects); thus, only a few studies allowed investigation into the role of HbA1c in colon and rectal cancers separately (15, 22, 23), and when this was the case, sample size and statistical power were generally limited. The majority of these studies included only women (21, 22, 24), mainly from North American populations (21-24).

Here, we present the results of the largest prospective study thus far on HbA1c percentages and the risk of cancers of the colon and of the rectum in women and in men, including 1,026 case subjects and 1,026 matched control subjects, who were part of the EPIC study.

Materials and Methods

Study Population and Blood Sample Collection. The EPIC cohort consists of about 370,000 women and 150,000 men, mainly ages 35 to 69 y, recruited from 1992 to 1998 in 23 research centers in 10 Western European countries (Denmark, France, Germany, Greece, Italy, Spain, Sweden, the Netherlands, and the United Kingdom; ref. 26). Blood samples were collected from about 65% of the women and 93% of the men according to a standardized protocol (26).

Extensive questionnaire data were collected on habitual diet and lifestyle variables (27). Height, weight, and waist and hip circumferences were measured for all subjects according to standardized protocols (26), except for part of the Oxford cohort, where height, weight, and body circumferences were self-reported.

The present study includes subjects from 20 recruitment centers in 8 of the participating countries: Denmark, France, Germany, Greece, Italy, Spain, the Netherlands, and the United Kingdom. Norway was not included in the current study because blood samples were only recently collected and very few colorectal cancer cases have occurred after blood donation. Sweden was not included because an independent study of HbA1c and colorectal cancer risk has already been undertaken (15).

Follow-up for Cancer Incidence and Vital Status. Follow-up for vital status was collected through record linkage with regional/national cancer registries in all countries except Germany and Greece, where data on vital status were collected through an active follow-up. Incident cancer cases were identified through record linkage with regional cancer registries in Denmark, the Netherlands, the United Kingdom, Spain, and in most of the Italian centers (complete to December 2001). In Germany, France, Greece, and Naples, follow-up (complete to December 2002) was based on a combination of methods, including health insurance records, cancer and pathology registries, and active follow-up through study subjects and their next-of-kin. For each EPIC study center, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status.

Selection of Case and Control Subjects. Case subjects were selected among men and women who developed colon or rectum cancers after their recruitment into the EPIC study, and before the end of the study period (defined for each study center by the latest end-date of follow-up). For the present study, colon cancers were defined as tumors in the cecum, appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, and descending and sigmoid colon (C18.0-C18.7 according to the 10th Revision of the International Statistical Classification of Diseases, Injury and Causes of Death), as

well as tumors that were overlapping or unspecified (C18.8 and C18.9). Cancers of the rectum were defined as tumors occurring at the recto-sigmoid junction (C19) or rectum (C20). Anal canal tumors were excluded. Colorectal cancer is defined as a combination of colon and rectal cancer cases.

Subjects who used any hormone replacement therapy or any exogenous hormones for contraception or medical purposes at blood donation (444 case women) and who had previous diagnosis of cancer (except nonmelanoma skin cancer), or who had missing information on fasting status (52 case subjects) were excluded from the study. A total of 1,026 incident cases of colorectal cancers (colon, $n = 644$; rectal, $n = 382$) were included in the present analyses as follows, divided by colon/rectum: 174/149 from Denmark, 14/1 from France, 14/13 from Greece, 75/52 from Germany, 101/41 from Italy, 62/36 from the Netherlands, 78/41 from Spain, and 126/49 from the United Kingdom.

For each case subject with colorectal cancer, one control subject was chosen at random among appropriate risk sets consisting of all cohort members alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case. An incidence density sampling protocol for control selection was used, such that controls could include subjects who became a case later in time, while each control subject could also be sampled more than once. Matching characteristics for cases and controls were the study center where the subjects were enrolled in the cohort, gender, age (± 6 mo) at enrollment, time of the day at blood collection, fasting status (<3 h; 3-6 h; >6 h), and follow-up time (9). Women were also matched for menopausal status (premenopausal, postmenopausal, and perimenopause/unknown), and premenopausal women were matched for phase of menstrual cycle at blood collection (28). These latter matching criteria were considered because a study on the relationship of endogenous hormones and colorectal cancer risk is being planned on the same population (9).

Subjects were defined as diabetics according to two different criteria: the first one was based on questionnaire data (for subjects who had, at the time of recruitment, answered "yes" to the question "Are you diabetic?"; $n = 98$), and the second one based on HbA1c percentages (subjects who answered "no" or had no answer at all to the previous question, but who had in the current study HbA1c levels $> 6.5\%$; $n = 113$). This percentage corresponds to the top 95th percentile of HbA1c levels of subjects who answered "no" to the question "Are you diabetic?").

All participants had given their consent for future analyses of their blood samples, and the internal review board of the IARC had approved the analyses of HbA1c.

Laboratory Assays. Measurements of HbA1c were done on erythrocyte hemolysate using the high-performance liquid chromatography method with Bio-Rad variant II instrument at Karolinska University Laboratory, Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden, and are expressed in U.S. National Glycohemoglobin Standardization Program units and as percentages of hemoglobin. Intra-batch coefficients of variations were 2.5% at 5.7 HbA1c percentages, and 2.4% at 9.8 HbA1c percentages.

Data Analyses. Case-control differences were assessed using paired t tests for continuous variables and paired χ^2 tests for categorical variables. Case-control differences in HbA1c percentages were tested by conditional logistic regression analyses and results reported in consequent tables.

Conditional logistic regressions using the SAS "PHREG" procedure (SAS Institute) were used to assess the risk for a unit increase with anthropometric and environmental factors such as body mass index (BMI), waist circumference, waist to hip ratio (WHR), physical activity, alcohol intake, and diabetes usually reported to be associated with colorectal cancer risk. As well, odds ratios (OR) for cancer risk by quintiles of HbA1c were estimated by conditional logistic regression. Quintile cutoff points were based on the distributions of controls. ORs were also estimated on a continuous scale for a 10% increase in HbA1c percentages, which approximately represents the increase in HbA1c percentages between the lowest and the highest quintiles of the study population. Multivariate conditional logistic regression was used to estimate ORs adjusted for possible confounders other than those controlled for by matching, including smoking status (never, former, current, or missing), physical activity (inactive, moderately inactive, moderately active, active, or missing), BMI, waist circumference, WHR, height, alcohol intake, fiber intake, and education. Only covariates that resulted as being statistically different between cases and matched controls (Table 1) were retained in the final model of analyses as confounding variables (WHR and alcohol consumption).

For analyses of statistical heterogeneity between study countries, gender, or fasting status, ORs were also estimated for continuous measurements of HbA1c on the $\log_{1.1}$ scale (10% increase in HbA1c percentage). Formal tests of heterogeneity between the ORs in different EPIC subgroups were based on χ^2 statistics, calculated as the deviations of logistic β -coefficients observed in each of the subgroups, relative to the overall β -coefficient.

All statistical analyses were done using the Statistical Analysis System (SAS) software package, version 8 (SAS Institute).

Results

Baseline characteristics of the study population by anatomic site are shown in Table 1. Colon cancer case subjects had higher BMI, WHR and HbA1c percentages, and larger waist circumference compared with the control group. These differences were mirrored in case and control subjects in the rectum subgroup, but none of these differences reached statistical significance. Cases of rectal cancer had a higher current alcohol consumption compared with the control subjects, but no such difference was noted for colon cancer. The same differences between case and control subjects as in the overall population were observed when analyses were stratified by gender, except for alcohol consumption: male case subjects had a higher alcohol intake compared with control subjects, whereas no significant case-control difference was observed for women.

On a continuous scale for a unit increase, BMI, waist circumference, WHR, and alcohol intake were directly

Table 1. Description of the study population, by colon and rectal anatomic site groupings

Variable	Colon			Rectum		
	Cases	Matched controls	<i>P</i> difference* tests.	Cases	Matched controls	<i>P</i> difference*
<i>n</i>	644	644	—	382	382	—
Male subjects, %	53.1	53.1	—	57.3	57.3	—
Nonfasting subjects, %	72.7	72.7	—	80.1	80.1	—
Mean age, y (5th-95th percentile)						
At recruitment	59.1 (46.1-71.6)	59.1 (46.2-71.6)	0.29	58.2 (47.7-69.7)	58.2 (47.7-69.5)	0.87
At blood donation	59.2 (46.1-71.6)	59.2 (46.2-71.7)	0.32	58.3 (47.7-69.7)	58.3 (48.0-69.7)	0.96
At diagnosis	62.2 (50.0-75.0)	—	—	61.4 (50.0-73.0)	—	—
Mean y of follow-up	3.5 (0.3-7.0)	—	—	3.6 (0.6-7.3)	—	—
Mean BMI (5th-95th percentile)	27.3 (21.2-34.9)	26.9 (21.1-33.7)	0.08	27.0 (21.2-33.9)	26.6 (21.5-32.5)	0.10
Mean waist circumference	92.6 (71.0-114.0)	90.7 (71.0-110.5)	0.001	91.9 (72.0-111.0)	90.7 (69.00-110.0)	0.10
Mean WHR (5th-95th percentile)	0.89 (0.73-1.03)	0.88 (0.73-1.03)	0.02	0.90 (0.73-1.05)	0.89 (0.72-1.04)	0.15
Alcohol intake, g/d	17.6 (0-62.3)	16.4 (0-60.7)	0.51	22.1 (0.003-75.5)	17.5 (0.002-60.5)	0.004
Past use of hormone therapy, % [†]						
Yes	19.2	15.6	0.19	11.0	17.8	0.08
Smoking status, % [‡]			0.43			0.81
Never	40.5	44.4		37.2	35.9	
Former	35.9	33.7		33.0	35.9	
Smoker	23.0	21.6		29.3	28.0	
Physical activity, % [§]			0.16			0.15
Inactive	16.6	13.0		16.2	13.9	
Moderately inactive	29.2	27.0		28.5	25.1	
Moderately active	43.8	48.3		43.2	44.0	
Active	9.5	11.0		11.5	14.9	
Geometric mean (5th-95th percentile)						
HbA1c, %	5.8 (5.2-7.1)	5.7 (5.1-6.6)		5.8 (5.1-7.5)	5.8 (5.1-6.8)	
Diabetic subjects from questionnaires, %	5.0	3.9		6.5	4.2	
Diabetic subjects HbA1c>6.5, %	9.9	6.5		11.5	8.9	
Diabetic subjects from questionnaires or HbA1c>6.5, %	11.5	7.6		13.1	10.0	

**P* values for differences in means between cases and controls determined by paired *t* tests, for smoking status and physical activity *P* values were determined by paired χ^2 tests.

[†] In women only.

[‡] Smoking status of the remaining subjects is missing.

[§] Physical activity status of the remaining subjects is missing.

^{||} Mean/median and 5th-95th percentile values refer to the non-logarithmically transformed distribution.

associated with an increase in colorectal cancer risk in the overall population [OR, 1.03; 95% confidence interval (CI), 1.00, 1.05 for BMI; OR, 1.02; 95% CI, 1.01, 1.03 for waist circumference; OR, 7.02; 95% CI, 1.69, 29.14 for WHR; and OR, 1.005; 95% CI, 1.001, 1.01 for alcohol, respectively].

Increasing HbA1c percentages in the overall population were associated with an increase in the risk of colorectal cancer (OR, 1.11; 95% CI, 1.03, 1.20, for a 10% increase in HbA1c), as well as of colon cancer only, but no statistically significant association was observed for rectal cancer separately (Table 2). Adjustment for WHR slightly reduced the association between HbA1c and colon cancer risk, which lost statistical significance. An increase in cancer risk with increasing HbA1c percentage was observed for left colon ($n = 304$; OR, 1.07; 95% CI, 0.92, 1.25 for a 10% increase in HbA1c), as well as for right colon ($n = 249$; OR, 1.14; 95% CI, 0.97, 1.35) separately, although neither association reached statistical significance. The associations between HbA1c percentages and cancer risk on the overall population remained virtually the same after the exclusion of subjects from the Norfolk cohort (part of the cases in the current study were already included in a previous publication; ref. 25). As well, when subjects who developed colorectal cancer less than 6 months after

blood donation were excluded from the analyses (63 case subjects), the association with risk remained practically unchanged. When subjects who developed cancer less than 1 year after blood donation (134 case subjects) were excluded, increasing HbA1c percentages were still associated with an increase in the risk of colorectal cancer, but this association lost statistical significance (OR, 1.07; 95% CI, 0.99, 1.16 for a 10% increase in HbA1c).

In men, no statistically significant association was observed at all between HbA1c percentages and colorectal cancer (Table 3) or in colon or rectal cancer separately. In women, conversely, a statistically significant increase in colorectal cancer risk (OR, 1.19; 95% CI, 1.04, 1.35 for a 10% increase in HbA1c) as well as in rectal cancer risk (OR, 1.24; 95% CI, 1.01, 1.52 for a 10% increase in HbA1c) was observed for increasing HbA1c percentages (Table 4). Adjustment for WHR and alcohol intake slightly reduced the association of HbA1c with rectal cancer risk. In the same population, an increase in the risk of colon cancer with increasing HbA1c percentages was observed, but this association did not reach statistical significance.

Among all cases and controls, a total of 211 subjects were identified as diabetics, according to baseline questionnaire data ($n = 98$) or according to their elevated HbA1c levels ($n = 113$); of these, 74 were among cases of

Table 2. Odds ratios of colorectal cancer (95% CI) by increase in HbA1c in cases and in matched controls in the study population, by cancer site

	Quintiles					OR per 10% increase in HbA1c
	1	2	3	4	5	
Colorectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	214/218	193/212	189/224	234/217	196/155	
Crude*	1.00	0.93 (0.71-1.23)	0.87 (0.66-1.16)	1.11 (0.84-1.47)	1.33 (0.98-1.80)	1.11 (1.03-1.20)
Adjusted †	1.00	0.96 (0.73-1.27)	0.88 (0.66-1.17)	1.13 (0.85-1.49)	1.30 (0.96-1.77)	1.10 (1.01-1.19)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	202/192	173/189	95/99	156/180	206/172	
Adjusted †	1.00	0.89 (0.66-1.19)	0.94 (0.66-1.33)	0.84 (0.61-1.14)	1.15 (0.85-1.57)	1.07 (0.90-1.27)
Colon	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	130/129	121/129	119/152	156/142	118/92	
Crude*	1.00	0.93 (0.65-1.33)	0.78 (0.55-1.11)	1.10 (0.77-1.55)	1.30 (0.88-1.91)	1.12 (1.01-1.24)
Adjusted †	1.00	0.97 (0.67-1.39)	0.80 (0.56-1.14)	1.10 (0.77-1.56)	1.25 (0.84-1.84)	1.09 (0.98-1.22)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	122/115	108/112	60/68	97/117	144/119	
Adjusted †	1.00	0.93 (0.64-1.37)	0.86 (0.55-1.34)	0.80 (0.54-1.17)	1.15 (0.79-1.68)	1.09 (0.88-1.34)
Rectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	84/89	72/83	70/72	78/75	78/63	
Crude*	1.00	0.93 (0.61-1.44)	1.08 (0.68-1.73)	1.15 (0.72-1.83)	1.40 (0.86-2.27)	1.10 (0.98-1.24)
Adjusted †	1.00	0.91 (0.59-1.42)	1.07 (0.66-1.73)	1.15 (0.72-1.85)	1.45 (0.88-2.38)	1.10 (0.97-1.25)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	80/77	65/77	35/31	59/63	62/53	
Adjusted †	1.00	0.81 (0.51-1.29)	1.12 (0.62-2.02)	0.91 (0.54-1.53)	1.17 (0.68-2.01)	1.04 (0.78-1.38)

*Analysis matched on EPIC recruitment center, gender, age at blood donation, time of the day at blood donation, follow-up time, fasting status and, in women, menopausal status and phase of the menstrual cycle for premenopausal women.

† Adjustment for WHR and alcohol (g/d).

colon cancer, and 50 were among cases of rectal cancer. Such diagnosis of diabetes was associated with an increase in the risk of cancers of the colorectum (OR, 1.53; 95% CI, 1.13, 2.07), colon (OR, 1.64; 95% CI, 1.10, 2.44), or rectum (OR, 1.39; 95% CI, 0.87, 2.20). A direct association of the risk of colorectal cancer, or of colon and rectal cancers separately, with diabetes was also observed in subjects who identified themselves as

diabetics in the baseline questionnaire at recruitment only ($n = 32$ for colon and 25 for rectum subsites), although these associations did not reach statistical significance.

When subjects defined as diabetics were excluded from the statistical analyses ($n = 211$), an increase in colorectal cancer risk with increasing HbA1c percentages was still observed, but was no longer statistically

Table 3. Odds ratios of colorectal cancer (95% confidence intervals) by increase in HbA1c in men, by cancer site

	Quintiles					OR per 10% increase in HbA1c
	1	2	3	4	5	
Colorectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	118/127	109/103	104/110	116/120	114/101	
Crude*	1.00	1.14 (0.79-1.65)	1.03 (0.71-1.51)	1.05 (0.72-1.54)	1.25 (0.84-1.86)	1.06 (0.96-1.18)
Adjusted †	1.00	1.17 (0.80-1.69)	1.04 (0.71-1.53)	1.09 (0.74-1.60)	1.25 (0.83-1.86)	1.06 (0.95-1.17)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	112/112	94/90	56/46	79/93	101/101	
Adjusted †	1.00	1.05 (0.71-1.56)	1.27 (0.78-2.05)	0.87 (0.57-1.33)	0.99 (0.65-1.51)	0.94 (0.75-1.17)
Colon	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	68/74	70/63	63/72	74/75	67/58	
Crude*	1.00	1.23 (0.75-2.03)	0.98 (0.60-1.61)	1.10 (0.67-1.80)	1.32 (0.78-2.23)	1.10 (0.96-1.26)
Adjusted †	1.00	1.31 (0.79-2.16)	1.03 (0.62-1.70)	1.12 (0.68-1.85)	1.27 (0.75-2.17)	1.08 (0.94-1.24)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	65/65	60/52	38/30	43/57	65/67	
Adjusted †	1.00	1.19 (0.69-2.05)	1.31 (0.71-2.43)	0.82 (0.46-1.45)	0.92 (0.54-1.58)	0.92 (0.68-1.23)
Rectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	50/53	39/40	41/38	42/45	47/43	
Crude*	1.00	1.03 (0.59-1.78)	1.15 (0.64-2.10)	1.01 (0.55-1.85)	1.19 (0.65-2.19)	1.02 (0.87-1.19)
Adjusted †	1.00	0.94 (0.53-1.65)	1.18 (0.63-2.20)	1.04 (0.55-1.94)	1.35 (0.71-2.56)	1.03 (0.88-1.21)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	47/47	34/38	18/16	36/36	36/34	
Adjusted †	1.00	0.84 (0.46-1.53)	1.34 (0.60-3.02)	1.01 (0.52-1.99)	1.17 (0.58-2.35)	0.97 (0.67-1.38)

*Analysis matched on EPIC recruitment center, gender, age at blood donation, time of the day at blood donation, follow-up time, fasting status and, in women, menopausal status and phase of the menstrual cycle for premenopausal women.

† Adjustment for WHR and alcohol (g/d).

Table 4. Odds ratios of colorectal cancer (95% confidence intervals) by increase in HbA1c in women, by cancer site

	Quintiles					OR per 10% increase in HbA1c
	1	2	3	4	5	
Colorectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	96/91	84/109	85/114	118/97	82/54	
Crude*	1.00	0.72 (0.47-1.09)	0.71 (0.46-1.09)	1.14 (0.75-1.73)	1.46 (0.91-2.33)	1.19 (1.04-1.35)
Adjusted †	1.00	0.74 (0.48-1.13)	0.71 (0.46-1.10)	1.13 (0.74-1.71)	1.40 (0.87-2.24)	1.16 (1.01-1.32)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	90/80	79/99	39/53	77/87	105/71	
Adjusted †	1.00	0.72 (0.46-1.13)	0.69 (0.41-1.16)	0.78 (0.49-1.23)	1.32 (0.83-2.10)	1.28 (0.99-1.67)
Colon	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	62/55	51/66	56/80	82/67	51/34	
Crude*	1.00	0.67 (0.39-1.13)	0.62 (0.37-1.04)	1.09 (0.66-1.79)	1.34 (0.75-2.38)	1.15 (0.97-1.37)
Adjusted †	1.00	0.69 (0.40-1.18)	(0.63 0.37-1.05)	1.09 (0.66-1.82)	1.30 (0.72-2.33)	1.12 (0.93-1.34)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	57/50	48/60	22/38	54/60	79/52	
Adjusted †	1.00	0.73 (0.42-1.27)	0.55 (0.28-1.06)	0.79 (0.46-1.37)	1.38 (0.80-2.38)	1.32 (0.96-1.80)
Rectum	≤5.4	[5.4-5.6]	[5.6-5.8]	[5.8-6.1]	>6.1	
No. cases/controls	34/36	33/43	29/34	36/30	31/20	
Crude*	1.00	0.84 (0.41-1.72)	0.95 (0.44-2.06)	1.29 (0.61-2.74)	1.75 (0.78-3.92)	1.24 (1.01-1.52)
Adjusted †	1.00	0.86 (0.41-1.78)	0.95 (0.44-2.07)	1.28 (0.60-2.73)	1.67 (0.74-3.78)	1.22 (0.99-1.50)
Nondiabetics	≤5.4	[5.4-5.6]	[5.6-5.7]	[5.7-5.9]	>5.9	
No. cases/controls	33/30	31/39	17/15	23/27	26/19	
Adjusted †	1.00	0.71 (0.32-1.55)	0.99 (0.40-2.46)	0.72 (0.30-1.72)	1.15 (0.47-2.79)	1.21 (0.74-1.97)

*Analysis matched on EPIC recruitment center, gender, age at blood donation, time of the day at blood donation, follow-up time, fasting status and, in women, menopausal status and phase of the menstrual cycle for premenopausal women.

† Adjustment for WHR and alcohol.

significant, and the same was true for cancers of the colon or rectum separately (Table 2). The same trend in results was also observed when analyses were stratified by gender and by anatomic subsite, although the association between increasing HbA1c percentages and colorectal cancer risk in women was of borderline significance (Tables 3 and 4).

Tests of heterogeneity showed no differences in the association of HbA1c with cancer risk by gender, fasting status, country, or age. No statistically significant interaction has been observed between WHR (below versus above the median of the study population, stratified by gender) and HbA1c percentages ($P_{\text{interaction}} = 0.70$ for women, and $P_{\text{interaction}} = 0.90$ for men). Adjustments for height, waist, education, fiber intake, BMI, physical activity, or smoking did not alter the estimated relationships.

Discussion

In this prospective study, the largest to date on the relationship between HbA1c and colorectal cancer, we observed a mild overall increase in the risk of colorectal cancer with increasing HbA1c percentages. The increase in risk was stronger in women than in men, and, among women, stronger for rectum than for colon cancer. When statistical analyses were restricted to nondiabetic subjects, HbA1c percentages were still associated with an increase in colorectal and colon cancer risk, but this increase was no longer statistically significant.

Previous studies on HbA1c and colorectal cancer risk indicated either an increase in colorectal cancer risk with increasing HbA1c percentages (23, 25) or no relationship at all (21, 22, 24). However, all previous studies included a fairly small number of cases (between 67 and 380), and most of these included only women (21, 22, 24). The data

from the current study suggest an implication of hyperglycemia in the development of colorectal cancer overall, as well as in colon and rectal cancers separately. Previous studies, including those conducted within the EPIC cohort, have consistently shown an increase in the risk of colorectal cancer, particularly of colon cancer, with excess body weight and obesity (1-3). Waist circumference and WHR, indicators of abdominal obesity and indices of hyperinsulinemia, showed the strongest and most consistent associations with risk among both men and women (4). The moderate association of colorectal cancer risk with HbA1c compared with the stronger association with abdominal obesity, observed as well in the present study, may suggest that the link between obesity and colorectal cancer is primarily mediated through mechanisms other than hyperglycemia, as hyperinsulinemia, fatty acid synthesis, lipids, or inflammation (29-33). On the other hand, the weakening of the estimates of HbA1c with cancer risk when adjusting by WHR does suggest that the relationship of WHR with colorectal cancer is partially (although modestly) mediated through hyperglycemia.

The association among HbA1c, diabetes, and colorectal cancer risk observed in the present study is less strong than the association observed in the study carried out previously within the EPIC-Norfolk cohort (25). This difference in the magnitude of associations may be due to the different criteria used for the inclusion of cancer cases (women taking exogenous hormones at the time of blood donation were excluded from the present study), or to different follow-up times.

In the current study, we used two different definitions of diabetes: the first definition was based on the information collected at blood donation; the second definition was based on HbA1c percentages. Because we did not have information about baseline glucose measurements, or oral glucose tolerance tests, we used

HbA1c as a proxy for the identification of hidden diabetes among the study subjects. We therefore defined as diabetics not only subjects with declared diabetes, but also all subjects that had HbA1c percentages >6.5%. This cutoff point is in accordance with the 2003 revised U.S. standard (American Diabetes Association³⁰; ref. 34), and in the Diabetes Guidelines Europe (IDDM consensus guidelines; ref. 35),³¹ in which percentages of HbA1c are considered normal when they are <6.1%. However, the use of HbA1c to identify diabetic subjects may have overestimated their percentage in our study population, because the use of HbA1c measurements by itself as a tool for the diagnosis of diabetes is still under debate (20, 36-38).

High plasma glucose concentrations have been related to a diet rich in fats and low in fibers, with low physical activity and therefore high adiposity, factors that have been shown to be related to higher colorectal cancer risk (1, 39, 40). A number of mechanisms through which hyperglycemia could increase cancer risk have been postulated, including the increase in pancreatic insulin secretion and blood levels (41, 42), the increased mitochondrial production of reactive oxygen species and oxidative stress ("glucose toxicity"; refs. 43, 44) leading to the generation of reactive oxygen species and chronic oxidative stress, and the enhanced activation of inflammatory pathways (45, 46). Another mechanism through which elevated glucose levels may enhance inflammatory responses is the increased endogenous formation of advanced glycation end products, which may activate the NF κ B pathway through a specific advanced glycation end products receptor. Chronically elevated plasma glucose concentrations can also favor tumor development through increases in cellular glucose levels, increases in cellular energy (ATP) levels, and reduced activity of AMP-activated protein kinase, which has a central role in the regulation of hepatic glucose metabolism as well as a tumor suppressor role (47, 48).

In the present study, we observed a stronger relationship between hyperglycemia and colorectal cancer risk in women than in men, and more strongly so for rectal cancer than for colon cancer, although the heterogeneity in the results between tumor subsites was not statistically significant. The difference in cancer association by gender cannot be explained by a different prevalence of diabetes in women compared with men, because in our study 11.9% of men and only 8.3% of women were defined as diabetics. This difference in association may be due to the interaction of some other female hormones influencing cancer risk (4, 49, 50). The results of our study confirm the relatively strong association of diabetes with colorectal cancer risk, which seems stronger for colon than for rectum cancer.

The current study has the advantage of having a substantial number of colorectal cancer cases, which allowed separate analyses by anatomic subsite (colon and rectum) and by gender with sufficient statistical power to detect significant associations, as well as by follow-up time. Another strength of the current study is its prospective design, which may reduce the possibility

that circulating levels of HbA1c could be influenced by the presence of the disease. A limitation of the current study is that only one single-blood sample has been collected per subject. HbA1c is an indicator of the average glycemia over the past 6 to 8 weeks, but how much one single HbA1c measurement could be representative of the exposure to glycemia over much longer periods is not known. Measurements of HbA1c in blood stored at -70°C have been seen to be stable over more than 10 years (51).

In conclusion, the results of the current study are supportive of a moderate role of hyperglycemia/hyperinsulinemia in colorectal cancer development. As suggested by our study results, this role could be more important in women than in men, and more for the development of rectal cancer than of colon cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Soheir Beshara, P. Matha, and Pernilla Lidbrandt for the excellent work in performing HbA1c analyses (Studiecenter fr Laboratoriemedicin, Karolinska Universitetslaboratoriet, L2:03, Karolinska Universitetssjukhuset Solna, Sweden), and Fatiha Louled for assistance with the formatting of the manuscript.

References

- Bianchini F, Kaaks R, Vainio H. Weight control and physical activity in cancer prevention. *Obes Rev* 2002;3:5-8.
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer* 2004;4:579-91.
- Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. *Gut* 2006;55:285-91.
- Pischoon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst* 2006;98:920-31.
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
- Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 1999;91:1147-54.
- Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. *J Natl Cancer Inst* 2000;92:1592-600.
- Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. *J Natl Cancer Inst* 2004; 96:546-53.
- Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2007;121:368-76.
- Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. *Diabetes Care* 2007;30:561-7.
- Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. *Cancer Epidemiol Biomarkers Prev* 2005;14:133-7.
- Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst* 1999;91:542-7.
- La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 1997;6: 1007-10.
- Keku TO, Lund PK, Galanko J, et al. Insulin resistance, apoptosis, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev* 2005;14:2076-81.

³⁰ <http://www.diabetes.org>

³¹ <http://www.idf.com>

15. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. *Int J Obes (Lond)* 2008;32:304–14.
16. Trevisan M, Liu J, Muti P, et al. Markers of insulin resistance and colorectal cancer mortality. *Cancer Epidemiol Biomarkers Prev* 2001;10:937–41.
17. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. *Cancer Epidemiol Biomarkers Prev* 2002;11:385–91.
18. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. *Science* 1978;200:21–7.
19. Davidson MB, Schriger DL, Peters AL, Lorber B. Glycosylated hemoglobin as a diagnostic test for type 2 diabetes mellitus. *JAMA* 2000;283:606–7.
20. Rohlfing CL, Little RR, Wiedmeyer HM, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. *Diabetes Care* 2000;23:187–91.
21. Platz EA, Hankinson SE, Rifai N, et al. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). *Cancer Causes Control* 1999;10:379–86.
22. Lin J, Ridker PM, Pradhan A, et al. Hemoglobin A1c concentrations and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* 2005;14:3010–2.
23. Saydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003;12:412–8.
24. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. *Cancer Epidemiol Biomarkers Prev* 2006;15:750–5.
25. Khaw KT, Wareham N, Bingham S, et al. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. *Cancer Epidemiol Biomarkers Prev* 2004;13:915–9.
26. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer* 2004;4:206–15.
27. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113–24.
28. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). *J Natl Cancer Inst* 2005;97:755–65.
29. Chapkin RS, Davidson LA, Ly L, et al. Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. *J Nutr* 2007;137:200–4S.
30. Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. *Curr Opin Gastroenterol* 2007;23:48–54.
31. Bird CL, Ingles SA, Frankl HD, et al. Serum lipids and adenomas of the left colon and rectum. *Cancer Epidemiol Biomarkers Prev* 1996;5:607–12.
32. Hall MN, Campos H, Li H, et al. Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16:314–21.
33. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the β -catenin connection. *Cancer Res* 2006;66:11085–8.
34. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003;26(Suppl 1):S5–20.
35. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. *Diabet Med* 1999;16:716–30.
36. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. *Clin Chem* 2007;53:897–901.
37. Manley S, John WG, Marshall S. Introduction of IFCC reference method for calibration of HbA: implications for clinical care. *Diabet Med* 2004;21:673–6.
38. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. *JAMA* 1996;276:1246–52.
39. Friedenreich C, Norat T, Steindorf K, et al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev* 2006;15:2398–407.
40. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. *Lancet* 2003;361:1496–501.
41. Bergman RN, Ader M, Huecking K, Van CG. Accurate assessment of β -cell function: the hyperbolic correction. *Diabetes* 2002;51(Suppl 1):S212–20.
42. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. *Diabetologia* 2004;47:943–56.
43. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. *Diabetes* 2004;53(Suppl 1):S119–24.
44. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β cells in diabetes. *J Biol Chem* 2004;279:42351–4.
45. Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. *J Biol Chem* 2005;280:4617–26.
46. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest* 2004;114:1752–61.
47. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. *Trends Endocrinol Metab* 2006;17:205–15.
48. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. *J Physiol* 2006;574:63–71.
49. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). *Cancer Causes Control* 2003;14:75–84.
50. Wolf LA, Terry PD, Potter JD, Bostick RM. Do factors related to endogenous and exogenous estrogens modify the relationship between obesity and risk of colorectal adenomas in women? *Cancer Epidemiol Biomarkers Prev* 2007;16:676–83.
51. Selvin E, Coresh J, Jordahl J, Boland L, Steffes MW. Stability of haemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade. *Diabet Med* 2005;22:1726–30.